Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes:Final results of an international prospective phase II trial

Haematologica

Volumn 96, Issue 9, 2011, Pages 1344-1350

  Ruutu, Tapani ^a   Volin, Liisa ^a   Beelen, Dietrich W ^b   Trenschel, Rudolf ^b   Finke, Juergen ^c   Schnitzler, Marc ^c   Holowiecki, Jerzy ^d,m   Giebel, Sebastian ^d,m   Markiewicz, Miroslaw ^d   Uharek, Lutz ^e   Blau, Igor W ^e   Kienast, Joachim ^f   Stelljes, Matthias ^f   Larsson, Kajsa ^g   Zander, Axel R ^h   Gramatzki, Martin ⁱ   Repp, Roland ⁱ   Einsele, Hermann ^j   Stuhler, Gernot ^j   Baumgart, Joachim ^k   Mylius, Heidrun A ^k   Pichlmeier, Uwe ^k   Freund, Mathias ^l   Casper, Jochen ^l,n   more..

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g KAROLINSKA INSTITUTE   (Sweden)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ UNIVERSITY OF KIEL   (Germany)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k MEDAC GMBH   (Germany)

^l UNIVERSITY OF ROSTOCK   (Germany)

^m INSTITUTE OF ONCOLOGY   (Poland)

ⁿ Clinic Oldenburg Clinic for Oncology and Hematology   (Germany)

more..

Author keywords

Fludarabine; Hematopoietic stem cell transplantation; Myelodysplastic syndrome; Reduced toxicity conditioning; Treosulfan

Indexed keywords

ATG FRESENIUS; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; THYMOCYTE ANTIBODY; TREOSULFAN; UNCLASSIFIED DRUG;

5Q- SYNDROME; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANOREXIA; ARTICLE; BILIARY TRACT DISEASE; BLEEDING; CARDIOTOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENDOCRINE DISEASE; ENGRAFTMENT; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEMOLYSIS; HUMAN; INCIDENCE; INFECTION; KARYOTYPE; MALE; MORTALITY; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL; OVERALL SURVIVAL; PAIN; PANCREAS DISEASE; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; RELAPSE; RESPIRATORY TRACT DISEASE; STOMATITIS; UROGENITAL TRACT DISEASE; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; BUSULFAN; CHIMERISM; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 80052360054     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.043810     Document Type: Article

References (44)

1. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant. 2006;37(12):1069-85.
2. Barrett AJ, Savani BN. Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol. 2008;45(1):49-59.
3. Martino R, Valcarcel D, Brunet S, Sureda A, Sierra J. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant. 2008;41(1): 33-8.
4. Marcondes M, Deeg HJ. Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom? Best Pract Res Clin Haematol. 2008;21(1):67-77.
5. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108(3):836-46.
6. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104(3):865-72.
7. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105(4):1810-4.
8. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20(2):322-8.
9. Van Pel M, van Breugel DW, Vos W, Ploemacher RE, Boog CJ. Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donorspecific tolerance for skin grafts across full MHC barriers. Bone Marrow Transplant. 2003;32(1):15-22.
10. van Pel M, van Breugel DWJG, Vos W, Ploemacher RE, Boog CJ. Towards a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers. Bone Marrow Transplant. 2004;33(2):153-9.
11. Ploemacher RE, Johnson KW, Rombouts EJC, Etienne K, Westerhof GR, Baumgart J, et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant. 2004;10:236-54.
12. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004;103(2):725-31.
13. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, et al. Doseescalated treosulfan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with complications. Bone Marrow Transplant. 2005;35(3):233-41.
14. Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as a preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 2006;37(4):339-44.
15. Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H, et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2007;39(7):389-96.
16. Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A, et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol. 2008;142(2):284-92.
17. Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C, et al. Treosulfanbased conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol. 2008;143(4):548-51.
18. Cutting R, Mirelman A, Vora A. Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation. Br J Haematol. 2008;143(5):748-51.
19. Greystoke B, Bonanomi S, Carr TF, Gharib M, Khalid T, Coussons M, et al. Treosulfancontaining regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant diseases and significant comorbidities. Br J Haematol. 2008;142(2): 257-62.
20. Slatter MA, Rao K, Amrolia P, Flood T, Abinun M et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency (PID): UK experience. Blood. 2011; 117(16)4367-75.
21. Wachowiak J, Sykora K-W, Cornish J, Chybicka A, Kowalczyk JR, et al. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant. 2011 Feb 07; Epub DOI:10.1038/bmt.2010.343.
22. Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, et al. Allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol. 2010;28(20):3344-51. Erratum in: J Clin Oncol. 2010;28(23):3797.
23. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44(6):778-83.
24. McDonald GB, Hinds MS, Fisher LBG, Schoch HG, Wolford JL, Banaji M, et al. Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255-67.
25. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. World Health Organization (WHO) International Working Group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671-4.
26. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestation of graft versus-host disease in human recipients of marrow from HLAmatched sibling donors. Transplantation. 1974;18(4):295-304.
27. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980; 69(2):204-17.
28. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GvHD grading. Bone Marrow Transplant. 1995; 15(6):825-8.
29. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88.
30. Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant. 2009;43(8):597-609.
31. Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2011;17(3):341-50.
32. Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N, et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant. 2007;40(9):843-50.
33. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, et al. Reducedintensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104(6):1616-23.
34. Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol. 2005;23(15):3439-46.
35. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20(1):128-35.
36. Scott B, Deeg HJ. Hematopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. Best Pract Res Clin Haematol. 2006;19(3):519-33.
37. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, et al. Conditioning with targeted busulfan and cyclophosphamide for hematopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100(4):1201-7.
38. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparatory regimens and analysis of prognostic factors. Blood.1996;87(1):51-8.
39. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome; outcomes analysis according to IPSS score. Leukemia. 1998;12(Suppl 1):S25-9.
40. de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica. 2010;95(10):1754-61.
41. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant. Epub 2011 Feb 18.
42. Sjoo F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M, et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol. 2006;34(1):115-21.
43. Shimoni A, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Nagler A. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stemcell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma. 2007;48(12): 2352-9.
44. Holowiecki J, Giebel S, Beelen D, Trenschel R, Wandt H, Schaefer-Eckart K, et al. Clinical phase II trial to evaluate the safety and efficacy of low-toxicity treosulfan/fludarabine conditioning prior to allogeneic haematopoietic stem cell transplantation in patients with acute myeloid leukaemia. Blood. 2007;110(11): Abstr. 621.